Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

Caro, JJ

doi:10.1016/s0149-2918(01)80087-4

Cited by 120 publications

(88 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Although some clinicians may challenge the clinical equivalence and therapeutic substitution of PPIs, [18][19][20][21] all drugs within this therapeutic category are known to be effective in both healing ulcerations and alleviating the symptoms of reflux. 22,23 The American Society of HealthSystem Pharmacists (ASHP) promulgated national guidelines for SUP in 1999.…”

Section: ■■ Discussionmentioning

confidence: 99%

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Thomas

Culley²,

Gladowski³

et al. 2010

JMCP

View full text Add to dashboard Cite

show abstract

Section: ■■ Discussionmentioning

confidence: 99%

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Thomas

Culley²,

Gladowski³

et al. 2010

JMCP

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis of prospective trials, 75-94% and 87% of patients achieved endoscopic remission after eight weeks of initial PPI treatment and one year of maintenance therapy, respectively (8). On the other hand, in the daily clinical setting, the endoscopic remission rate following PPI therapy remains obscure.…”

Section: Introductionmentioning

confidence: 99%

Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients

et al. 2013

View full text Add to dashboard Cite

Objective Proton pump inhibitors (PPIs) are widely used as the mainstay of treatment for erosive reflux esophagitis, based on the excellent results obtained in clinical trials. However, the endoscopic remission rates in patients treated with PPIs in actual clinical settings have not been fully assessed. We conducted a nationwide survey to evaluate the effectiveness of PPIs based on endoscopic findings in real-world clinical settings. Methods This was a multicenter retrospective study conducted among 41 Japanese institutions. Endoscopic findings before and after PPI therapy were collected from the medical records of patients diagnosed with Los Angeles grade A-D reflux esophagitis who had been treated with a PPI for at least eight weeks before undergoing a second endoscopy. The remission rates of erosive esophagitis, defined as the percentage of patients with grade N or M findings following PPI therapy, were calculated. Results Data for 541 patients were analyzed. At first endoscopy, 45.5%, 30.3%, 15.9% and 8.3% of patients were diagnosed with grade A, B, C and D esophagitis, respectively. The mean duration of PPI therapy was 410 days, and the mean remission rate was 61.6%. The remission rate was significantly lower in the patients with more severe erosive esophagitis based on the LA grade before PPI therapy. Conclusion This study revealed that approximately 40% of the patients did not achieve remission of erosive esophagitis following PPI therapy for a mean of 1.1 years. This suggests the necessity of providing careful follow-up using periodic endoscopy and appropriately selecting PPI therapy.

show abstract

“…Thus, comparative studies have demonstrated that protonpump inhibitors provided far superior GERD healing compared with histamine H 2 -receptor antagonists (H 2 -RAs). [1][2][3][4][5][6][7][8][9][10][11] In Japan, omeprazole 10 mg, as well as 20 mg, is widely used as maintenance therapy for GERD. Hallerback et al reported that maintenance therapy with omeprazole 10 mg was superior to ranitidine 300 mg 5 .…”

Section: Introductionmentioning

confidence: 99%

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂‐receptor antagonist

Shimatani

Inoue

Kuroiwa

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Omeprazole 10 mg is used as maintenance therapy for gastro-oesophageal reflux disease, but previous reports have not mentioned the potency of its acid suppression. Aim: To evaluate the potency of acid suppression with omeprazole 10 mg, in relation to CYP2C19 genotypes. Methods: Eighteen healthy subjects without Helicobacter pylori participated. After a 7-day regimen of omeprazole 10 mg, 20 mg, lafutidine 20 mg (a novel H 2 -receptor antagonist) or water only (baseline data), intragastric pH was measured for 24 h. Results: With omeprazole 10 mg, greater differences were observed than 20 mg in median pH values and pH > 4 holding time ratios between poor metabolizers (PMs, n ¼ 6) and the others [homozygous extensive metabolizers (homo-EMs, n ¼ 6) and heterozygous extensive metabolizers (hetero-EMs, n ¼ 6)]. With lafutidine 20 mg, these parameters were not influenced by the genotype. The potency of acid suppression was: omeprazole 20 mg lafutidine 20 mg > omeprazole 10 mg in homo-EMs, omeprazole 20 mg > omeprazole 10 mg lafutidine 20 mg in hetero-EMs, and omeprazole 20 mg omeprazole 10 mg > lafutidine 20 mg in PMs. Conclusions: Omeprazole 10 mg strongly suppresses acid secretion, but depending on the CYP2C19 genotypes shows greater interindividual variations in suppression than 20 mg.

show abstract

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

Cited by 120 publications

References 50 publications

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂‐receptor antagonist

Contact Info

Product

Resources

About

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

Cited by 120 publications

References 50 publications

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2‐receptor antagonist

Contact Info

Product

Resources

About

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂‐receptor antagonist